Open Access
Issue
EPJ Nonlinear Biomed Phys
Volume 3, Number 1, December 2015
Article Number 6
Number of page(s) 18
DOI https://doi.org/10.1140/epjnbp/s40366-015-0023-3
Published online 11 August 2015
  1. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression. Comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4–13. [Google Scholar]
  2. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16:1–11. [Google Scholar]
  3. Neves RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515–27. [Google Scholar]
  4. Heiser LM, Sadanandam A, Kuo W-L, Benz SC, Goldstein TC, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Sci Acad USA. 2012;109:2724–9. [Google Scholar]
  5. Shannon CE. A mathematical theory of communication. Bell Syst Tech J. 1948;27(3):379–423. doi:10.1002/j.1538-7305.1948.tb01338.x. [Google Scholar]
  6. Breitkreutz D, Hlatky L, Rietman EA, Tuszynski JA. Molecular signaling network complexity is correlated with cancer patient survivability. Proc Natl Acad Sci U S A. 2012;109:9209–12. [Google Scholar]
  7. Carels N, Tilli T, Tuszynski JA. A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases. PLoS One. 2015;10:e0115054. [Google Scholar]
  8. Breitkreutz D, Rietman EA, Hinow P, Healey L, Tuszynski JA. Complexity of molecular signaling networks for various types of cancer and neurological diseases correlates with patient survivability. In: BIOMAT 2013. Singapore: World Scientific; 2014. p. 250–62. [Google Scholar]
  9. Shepelev V, Fedorov A. Advances in the exon-intron database. Brief Bioinform. 2006;7:178–85. [Google Scholar]
  10. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5:621–8. [Google Scholar]
  11. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185–93. [Google Scholar]
  12. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368–76. [Google Scholar]
  13. Carels N, Frias D. A statistical method without training step for the classification of coding frame in transcriptome sequences. Bioinformatics Biol Insights. 2013;7:35–54. [Google Scholar]
  14. Kim M-S, Pinto SM, Getnet D, Nirujogi RS, Manda SS, et al. A draft map of the human proteome. Nature. 2014. doi:10.1038/nature13302. [Google Scholar]
  15. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282–303. [Google Scholar]
  16. Bury M, Andolfi A, Rogister B, Cimmino A, Mégalizzi V, et al. Fusicoccin a, a phytotoxic carbotricyclic diterpene glucoside of fungal origin, reduces proliferation and invasion of glioblastoma cells by targeting multiple tyrosine kinases. Transl Oncol. 2013;6:112–23. [Google Scholar]
  17. Cao W, Yang X, Zhou J, Teng Z, Cao L, et al. Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice. Apoptosis. 2010;15:230–41. [Google Scholar]
  18. Dong S, Kang S, Lonial S, Khoury HJ, Viallet J, Chen J. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia. 2008;22:572–7. [Google Scholar]
  19. Gay B, Suarez S, Caravatti G, Furet P, Meyer T, Schoepfer J. Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int J Cancer. 1999;83:235–41. [Google Scholar]
  20. Giubellino A, Gao Y, Lee S, Lee MJ, Vasselli JR, et al. Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res. 2007;67:6012–6. [Google Scholar]
  21. Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, et al. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene. 2008;27:4210–20. [Google Scholar]
  22. Ren H, Chu Z, Mao L. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther. 2009;8:1106–12. [Google Scholar]
  23. Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, et al. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6:519–31. [Google Scholar]
  24. Flor HH. Current status of the gene-for-gene concept. Annu Rev Phytopathol. 1971;9:275–96. [Google Scholar]
  25. Patocchi A, Walser M, Tartarini S, Broggini GAL, Gennari F, Sansavini S, et al. Identification by genome scanning approach (GSA) of a microsatellite tightly associated with the apple scab resistance gene Vm. Genome. 2005;48:630–6. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.